<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401222</article-id><article-id pub-id-type="pmc">PMC12092383</article-id><article-id pub-id-type="doi">10.3389/fcvm.2025.1571185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Machine learning algorithms to predict heart failure with preserved ejection fraction among patients with premature myocardial infarction</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Jing-xian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1580798/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Chang-ping</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Zhuang</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1562941/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Yan</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yu-hang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yu</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Yin</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1109016/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gao</surname><given-names>Jing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1581096/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Clinical School of Thoracic, Tianjin Medical University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>School of Public Health, Tianjin Medical University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Department of Cardiology, Tianjin Chest Hospital</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff4"><label><sup>4</sup></label><institution>Chest Hospital, Tianjin University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff5"><label><sup>5</sup></label><institution>Cardiovascular Institute, Tianjin Chest Hospital</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><aff id="aff6"><label><sup>6</sup></label><institution>Tianjin Key Laboratory of Cardiovascular Emergency and Critical Care</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Quan Huynh, University of Tasmania, Australia</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Cheng Hwee Soh, Baker Heart and Diabetes Institute, Australia</p><p>Binyam Tariku Seboka, Baker Heart and Diabetes Institute, Australia</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Yin Liu <email>liuyin2088@163.com</email> Jing Gao <email>gaojing2089@163.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#x02020;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1571185</elocation-id><history><date date-type="received"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Wang, Li, Cui, Liang, Wang, Zhou, Liu and Gao.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Li, Cui, Liang, Wang, Zhou, Liu and Gao</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>Heart Failure with Preserved Ejection Fraction (HFpEF) in patients with Premature Myocardial Infarction (PMI) is a crucial factor affecting long-term prognosis. This study aims to develop a model based on a machine learning algorithm that can predict the risk of in-hospital HFpEF in patients with PMI early and quickly.</p></sec><sec><title>Methods</title><p>This prospective study consecutively included PMI patients from January 2017 to December 2022. Lasso-Logistic, XGBoost, Random Forest, K-Nearest Neighbor, and Support Vector Machine models were constructed. The prediction performance of the models was compared through AUC, Accuracy, Precision, F1 score, and Brier score. Shapley Additive exPlanations is used to explain the model. A prediction system was developed to identify high-risk patients.</p></sec><sec><title>Results</title><p>The study finally included 840 PMI patients. 268 (31.90%) developed in-hospital HFpEF. The XGBoost model has the best prediction performance (AUC 0.854; Accuracy 0.798; Precision 0.686; F1 score 0.586; Brier score 0.143). The final model included ten variables, which were Brain natriuretic peptide (BNP)&#x02009;&#x0003e;&#x02009;100pg/ml, SYNTAX Score&#x02009;&#x0003e;&#x02009;14.5, Age, Monocyte to Lymphocyte Ratio (MLR)&#x02009;&#x0003e;&#x02009;0.3, Hematocrit (HCT)&#x02009;&#x0003c;&#x02009;45%, Heart rate (HR)&#x02009;&#x0003e;&#x02009;75 bpm, Body Mass Index (BMI)&#x02009;&#x02265;&#x02009;24&#x02005;kg/m<sup>2</sup>, C-reactive Protein to Lymphocyte Ratio (CLR)&#x02009;&#x0003e;&#x02009;2.83, Hypertension and Fibrinogen (Fg)&#x02009;&#x0003e;&#x02009;4&#x02005;g/L.</p></sec><sec><title>Conclusions</title><p>The explainable prediction model established based on the XGBoost algorithm can accurately predict the risk of in-hospital HFpEF in PMI patients and is available at <ext-link xlink:href="https://hfpefpmi.shinyapps.io/apppredict/" ext-link-type="uri">https://hfpefpmi.shinyapps.io/apppredict/</ext-link>. This system is expected to assist clinicians in decision-making by providing timely, prioritized, and precise interventions for PMI patients, ultimately reducing the incidence of HFpEF and improving long-term prognosis.</p></sec></abstract><kwd-group><kwd>premature myocardial infarction</kwd><kwd>heart failure with preserved ejection fraction</kwd><kwd>machine learning</kwd><kwd>XGBoost</kwd><kwd>prediction</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Key Project of Scientific and Technological Support Plan of Tianjin</funding-source><award-id award-type="contract" rid="cn001">2020, 20YFZCSY00820</award-id></award-group><award-group><funding-source id="cn002">Tianjin Health Research Project</funding-source><award-id award-type="contract" rid="cn002">TJWJ2022XK032</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Key Project of Scientific and Technological Support Plan of Tianjin in 2020 [No. 20YFZCSY00820] and the Tianjin Health Research Project [No. TJWJ2022XK032].</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="38"/><page-count count="11"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Heart Failure and Transplantation</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The risk of heart failure (HF) remains after premature myocardial infarction (PMI) and is a determinant of poor prognosis (<xref rid="B1" ref-type="bibr">1</xref>). Heart Failure with Preserved Ejection Fraction (HFpEF) is defined as HF with a left ventricular ejection fraction (LVEF) &#x02265;50%. As a result of improved treatments and increased public awareness of HFpEF, the proportion of HFpEF in HF has increased to approximately 50%, affecting up to 32 million people worldwide (<xref rid="B2" ref-type="bibr">2</xref>). Previous studies have shown that 30%&#x02013;60% of patients with HFpEF have a history of acute myocardial infarction (AMI) (<xref rid="B3" ref-type="bibr">3</xref>). The in-hospital occurrence of HFpEF after AMI significantly affects the long-term prognosis, especially in the younger population, where patients suffer from decreased or even loss of their labor capacity, which in turn triggers a significant increase in the cost of medical care and creates a massive burden on the family and society (<xref rid="B4" ref-type="bibr">4</xref>). Therefore, a rapid, accurate, and reliable comprehensive algorithm to assess the risk in this specific group is needed for the early identification of high-risk patients with poor prognosis and for the timely improvement of long-term prognosis and quality of survival through personalized treatment.</p><p>While logistic regression (LR) remains computationally efficient and highly interpretable, it is constrained by its linear assumption, making it difficult to capture complex interactions. Additionally, LR struggles with high-dimensional data, relies heavily on manual feature selection, and is sensitive to outliers and missing values. In contrast, machine learning (ML) has gained increasing attention in cardiovascular disease prediction due to its ability to process large-scale clinical data and uncover intricate patterns (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Various ML algorithms have been widely applied to classification and predictive tasks. Among them, Extreme Gradient Boosting (XGBoost) has gained prominence for its ability to integrate multiple weak learners through a gradient boosting tree framework, achieving superior predictive performance while effectively mitigating overfitting risk (<xref rid="B7" ref-type="bibr">7</xref>). This ensemble approach performs exceptionally well in both binary and multiclass classification tasks and often outperforms traditional logistic regression models in clinical prediction settings (<xref rid="B8" ref-type="bibr">8</xref>). Random Forest (RF) is another ensemble learning method that constructs multiple decision trees and combines their outputs through averaging or majority voting, thereby enhancing model generalizability and reducing variance (<xref rid="B9" ref-type="bibr">9</xref>). K-Nearest Neighbors (KNN) is a simple yet effective classification algorithm that assigns class labels based on the proximity of data points (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Support Vector Machine (SVM) constructs an optimal hyperplane to maximize the margin between different classes, making it well-suited for binary classification tasks in structured datasets (<xref rid="B12" ref-type="bibr">12</xref>). Previous studies have demonstrated that XGBoost excels in predicting 30-day readmission in HF patients (<xref rid="B13" ref-type="bibr">13</xref>), AMI outcomes (<xref rid="B14" ref-type="bibr">14</xref>), ICU mortality (<xref rid="B15" ref-type="bibr">15</xref>), and acute kidney injury (<xref rid="B16" ref-type="bibr">16</xref>), whereas Random Forest has shown superior performance in postoperative delirium prediction (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Despite numerous advances, few applications of machine learning have been addressed in predicting HFpEF events during hospitalisation in patients with PMI. Given that PMI patients may exhibit unique risk factors, this study leverages the strengths of multiple ML algorithms to develop a predictive model integrating multidimensional clinical features of PMI patients. Specifically, we aim to identify key predictive factors, quantify their contributions, and provide a foundation for risk stratification and early intervention in this high-risk cohort.</p></sec><sec id="s2"><title>Material and methods</title><sec id="s2a"><title>Study population</title><p>The flow of the study is shown in <xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>. This is a single-center, prospective, observational cohort study. Consecutive patients admitted to Tianjin Chest Hospital for AMI between January 2017 and December 2022, meeting the PMI age threshold, were included in the PMI cohort. The inclusion criteria were as follows: (a) Age&#x02009;&#x0003e;&#x02009;18 years, with male&#x02009;&#x02264;&#x02009;50 years and female&#x02009;&#x02264;&#x02009;55 years; (b) First diagnosis of AMI upon admission, meeting the universal definition including clinical symptoms, typical changes in the electrocardiogram, and elevated cardiac biomarkers (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). (c) No occurrence of HF upon admission; (d) Undergoing coronary angiography (CAG) and primary percutaneous coronary intervention (PPCI). CAG and PPCI were performed by two or more cardiologists qualified in coronary diagnosis and treatment at our center.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Flow chart of the study. AMI, acute myocardial infarction; CA. G, coronary angiography; DCA, decision curve analysis; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; PPCI, primary percutaneous coronary intervention; PMI, premature myocardial infarction; SHAP: shapley additive exPlanations; NRI, net reclassification improvement; IDI, integrated discriminant improvement.</p></caption><graphic xlink:href="fcvm-12-1571185-g001" position="float"/></fig><p>The exclusion criteria were as follows: (a) Patients with severe liver and/or renal failure; (b) Patients with congenital heart disease and/or valvular heart disease; (c) Patients with severe inflammatory diseases and/or malignant tumors; (d) Patients with missing transthoracic echocardiography and/or other data; (e) Patients without signed informed consent. This study was conducted in accordance to the Declaration of Helsinki and was approved by the Ethics Committee of Tianjin Chest Hospital (No. 2017KY-007-01).</p></sec><sec id="s2b"><title>Data collection</title><p>We developed a structured electronic medical record database specifically for PMI patients at our hospital. This database was designed to standardize data collection and facilitate analysis. The collected data includes age, sex, body mass index (BMI), smoking and alcohol habits, family history of coronary artery disease (CAD), previous history, type of AMI; admission vital signs; laboratory examinations, CAG, and transthoracic echocardiography (TTE) parameters. TTE was conducted by certified sonographers following a standardized image acquisition protocol and utilizing consistent imaging equipment to capture the final result before discharge. Inflammatory biomarkers were determined using the following formulas, CLR (C-reactive Protein (mg/L) to Lymphocyte (*10<sup>9</sup>/L) ratio) and MLR (Monocyte (*10<sup>9</sup>/L) to Lymphocyte (*10<sup>9</sup>/L) ratio). The SYNTAX Score (<xref rid="B20" ref-type="bibr">20</xref>) was utilized to evaluate the severity of CAD and to aid in risk stratification and the planning of revascularization strategies among patients with CAD. It was calculated using software available online (<ext-link xlink:href="https://syntaxscore.org/" ext-link-type="uri">https://syntaxscore.org/</ext-link>). In addition, we recorded the patient's medication status during hospitalization, including antiplatelet drugs, statins, diuretics, angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and beta-blockers.</p></sec><sec id="s2c"><title>Study endpoint</title><p>All patients had a TTE assessment before discharged. HF was defined according to the criteria established by the guidelines for HF (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). The diagnostic criteria for HFpEF are as follows:
<list list-type="simple"><list-item><label>(1)</label><p>Presence of at least one typical heart failure symptom (e.g., exertional dyspnea, orthopnea) AND/OR one clinical sign of fluid retention (e.g., jugular venous distension, pulmonary rales, Leg edema).</p></list-item><list-item><label>(2)</label><p>Objective evidence of cardiac congestion demonstrated by either:
<list list-type="simple"><list-item><label>(a)</label><p>Hemodynamic confirmation <italic>via</italic> right heart catheterization [resting pulmonary capillary wedge pressure (PCWP)&#x0003e;15&#x02005;mmHg],</p></list-item><list-item><label>(b)</label><p>tructural/functional abnormalities through imaging: Thoracic radiography demonstrating pulmonary vascular redistribution or interstitial edema; Echocardiographic indices elevated <italic>E</italic>/<italic>e</italic>&#x02032; ratio (&#x0003e;13).</p></list-item></list></p></list-item><list-item><label>(3)</label><p>Echocardiography indicates that the LVEF is &#x02265;50%.</p></list-item></list></p></sec><sec id="s2d"><title>Model construction and validation</title><p>The minimum sample size required to construct the predictive model based on the pmsampsize criterion proposed by Riley et al. (<xref rid="B23" ref-type="bibr">23</xref>) requires the inclusion of at least 298 subjects. The missing rate of each variable was less than 5%; we used the median to fill in the missing values for continuous variables and conducted multiple imputations for categorical variables. The parameters for multiple imputation were set as m&#x02009;=&#x02009;5, method&#x02009;=&#x02009;NULL, maxit&#x02009;=&#x02009;50, and seed&#x02009;=&#x02009;123. The number of missing values for each variable and the analysis results of the dataset before and after imputation are presented in <xref rid="s12" ref-type="sec">Supplementary Table S1</xref>. To construct the model, the dataset is first randomly divided into: 80% as a training set for model training and cross-validation, and 20% as a testing set for final model evaluation. Within the training set, a five-fold cross-validation is further employed. The training data is randomly partitioned into five equal folds. For each iteration, four folds are selected for training, and one fold is used for validation. This process is repeated five times to optimize hyperparameters and reduce the risk of overfitting. The final model is evaluated using the 20% testing set to ensure a true assessment of its generalization performance. Considering the wide range of intervals for the different variables, as well as achieving the goal of rapid clinical application of the prediction system, we converted continuous variables other than age into categorical variables for analysis based on reference ranges, guidelines, or medians, and normalized age by a min-max scaling. Specifically, BMI was classified according to the Chinese population's overweight standard (24&#x02005;kg/m<sup>2</sup>) (<xref rid="B24" ref-type="bibr">24</xref>). Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), white blood cell count (WBC), neutrophils percentage (NEU%), hematocrit (HCT), hemoglobin (Hb), platelet count (PLT), total bilirubin (TBil), creatinine (Cr), uric acid (UA), homocysteine (HCY), glucose (Glu), glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), free fatty acids (FFA), C-reactive protein (CRP), D-dimer, fibrinogen (Fg), and brain natriuretic peptide (BNP) were classified according to their normal value reference ranges or guideline recommendations for classification. We classified total bile acids (TBA), CLR, MLR, creatine kinase isoenzyme (CK-MB), cardiac troponin T (cTnT), and SYNTAX scores according to the median of the dataset due to the lack of clear classification criteria. The number of HFpEF patients in this study is lower than that of non-HF patients. This imbalance in the data samples could significantly impact the performance of the prediction model. Therefore, we use the Synthetic Minority Over-sampling Technique (SMOTE) to balance the data set in the training set. The k-Nearest Neighbor (k-NN) threshold used in SMOTE is 5, and the over-sampling ratio is 1. This technique involves increasing the number of samples in the minority class by synthesizing new samples. Achieving a balanced number of samples in the data set is crucial for improving the model's training effectiveness (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Five ML models, Least absolute shrinkage and selection operator (Lasso)-Logistic, RF, XGBoost, KNN, and SVM, were constructed using the data from the training set with whether or not an in-hospital HFpEF occurred as the outcome event. Gradient boosting technology is based on decision trees. Variance inflation factor (VIF) was used to assess multicollinearity among predictor variables, and variables with VIF greater than 10 were excluded. Lasso is a regularization technique that performs variable selection and coefficient estimation by imposing constraints on the sum of the absolute values of the model parameters. This process causes some coefficients to be reduced to zero, effectively excluding them from the final model. Using the variables screened by Lasso, a two-category logistic risk prediction model is constructed. The modeling process of the other four models (RF, XGBoost, KNN, and SVM) is as follows. First, all variables are trained. To optimize the model's performance, the automatic parameter adjustment strategy is adopted, and a 5-fold cross-validation is used as the re-sampling strategy to evaluate the model's generalization ability. To further optimize model performance, we rank the variables based on their importance and select the top 10 features for retraining, following the same procedure as described above.</p></sec><sec id="s2e"><title>Statistical analysis</title><p>Shapiro&#x02013;Wilk test was used to evaluate the normality of continuous variables. Mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) or median (interquartile) was used to describe variables according to the evaluation results. <italic>T</italic>-test or Mann&#x02013;Whitney test was used for inter-group comparison. The categorical variables were expressed as numbers and percentages, and the chi-square test or Fisher's exact test was used for intergroup comparisons.</p><p>To evaluate the models, the area under the curve (AUC), Precision, Accuracy, F1 score, and Brier score were calculated in the testing set. Net Reclassification Improvement (NRI) and Integrated Discriminant Improvement (IDI) are used to assess the enhancement of the predictive model. According to the comparison results, the model with the best comprehensive performance was selected to construct the in-hospital HFpEF prediction model of PMI patients. The final model is explained using Shapley Additive exPlanations values (SHAP). Calibration curves determine how close the model's predicted probabilities are to the actual observed probabilities. Decision Curve Analysis (DCA) quantifies the net benefit of using the model at different thresholds and assesses the utility of the model in decision-making. Finally, a visual online prediction system was constructed to calculate the prediction probability for clinical application.</p><p>All statistical analyses were performed in SPSS Statistics 26.0 (IBM, Chicago, USA) and R software (version 4.3.1). Specifically, SPSS was used for descriptive statistics (normality tests, means, standard deviations and frequency distributions), and basic inferential analyses (<italic>t</italic>-tests, one-way ANOVA, and chi-square tests). R was employed for model construction, validation, performance evaluation and visualization analysis. A two-sided <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Baseline characteristics</title><p>The baseline characteristics of the study population, stratified into the HFpEF group (<italic>n</italic>&#x02009;=&#x02009;268) and the Non-HF group (<italic>n</italic>&#x02009;=&#x02009;572), are presented in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>. The total cohort comprised 840 participants, with a median age of 42[38&#x02013;44] years and a pronounced male predominance (91.0% males vs. 9.0% females). Notably, significant differences were observed between the two groups. The HFpEF group had a higher proportion of females compared to the Non-HF group (15.7% vs. 5.9%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and a slightly older median age (42 [39&#x02013;45] vs. 41 [37&#x02013;44] years, <italic>P</italic>&#x02009;=&#x02009;0.001). Additionally, participants with HFpEF exhibited a higher prevalence of obesity (BMI&#x02009;&#x02265;&#x02009;24&#x02005;kg/m<sup>2</sup>: 82.5% vs. 74.5%, <italic>P</italic>&#x02009;=&#x02009;0.013) and hypertension (56.3% vs. 45.8%, <italic>P</italic>&#x02009;=&#x02009;0.006). Laboratory and clinical findings further distinguished the groups. The HFpEF group demonstrated elevated markers of inflammation (CRP &#x0003e;5.0&#x02005;mg/L: 63.4% vs. 43.5%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; MLR &#x0003e;0.3: 65.7% vs. 42.7%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and cardiac dysfunction (BNP &#x0003e;100&#x02005;pg/ml: 91.0% vs. 62.4%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Coronary angiography revealed more severe coronary artery disease in HFpEF patients, as evidenced by a higher SYNTAX Score &#x0003e;14.5 (64.2% vs. 43.0%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of the hFpEF group and Non-HF group.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" rowspan="1" colspan="1">Total (<italic>n</italic>&#x02009;=&#x02009;840)</th><th valign="top" align="center" rowspan="1" colspan="1">Non-HF (<italic>n</italic>&#x02009;=&#x02009;572)</th><th valign="top" align="center" rowspan="1" colspan="1">HFpEF (<italic>n</italic>&#x02009;=&#x02009;268)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">76 (9.0)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (15.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">764 (91.0)</td><td valign="top" align="center" rowspan="1" colspan="1">538 (94.1)</td><td valign="top" align="center" rowspan="1" colspan="1">226 (84.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years) Median (Q1, Q3)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (38, 44)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (37, 44)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (39, 45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI&#x02009;&#x02265;&#x02009;24&#x02005;kg/m<sup>2</sup>, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">647 (77.0)</td><td valign="top" align="center" rowspan="1" colspan="1">426 (74.5)</td><td valign="top" align="center" rowspan="1" colspan="1">221 (82.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Smoke, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">597 (71.1)</td><td valign="top" align="center" rowspan="1" colspan="1">417 (72.9)</td><td valign="top" align="center" rowspan="1" colspan="1">180 (67.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.104</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alcohol, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">322 (38.3)</td><td valign="top" align="center" rowspan="1" colspan="1">219 (38.3)</td><td valign="top" align="center" rowspan="1" colspan="1">103 (38.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family history of CAD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (12.4)</td><td valign="top" align="center" rowspan="1" colspan="1">75 (13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (10.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.408</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Previous history</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">413 (49.2)</td><td valign="top" align="center" rowspan="1" colspan="1">262 (45.8)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (56.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">196 (23.3)</td><td valign="top" align="center" rowspan="1" colspan="1">132 (23.1)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (23.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.866</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">221 (26.3)</td><td valign="top" align="center" rowspan="1" colspan="1">155 (27.1)</td><td valign="top" align="center" rowspan="1" colspan="1">66 (24.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.500</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Type of AMI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSTEMI</td><td valign="top" align="center" rowspan="1" colspan="1">220 (26.2)</td><td valign="top" align="center" rowspan="1" colspan="1">168 (29.4)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (19.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">STEMI</td><td valign="top" align="center" rowspan="1" colspan="1">620 (73.8)</td><td valign="top" align="center" rowspan="1" colspan="1">404 (70.6)</td><td valign="top" align="center" rowspan="1" colspan="1">216 (80.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Admission vital signs</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HR&#x02009;&#x0003e;&#x02009;75&#x02005;bpm, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (11.7)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (8.9)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (17.5)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SBP&#x02009;&#x0003e;&#x02009;140&#x02005;mmhg, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">832 (99.1)</td><td valign="top" align="center" rowspan="1" colspan="1">567 (99.1)</td><td valign="top" align="center" rowspan="1" colspan="1">265 (98.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.715</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DBP&#x02009;&#x0003e;&#x02009;90&#x02005;mmhg, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">182 (21.7)</td><td valign="top" align="center" rowspan="1" colspan="1">123 (21.5)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (22.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.938</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Laboratory examination</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">WBC&#x02009;&#x0003e;&#x02009;10*10<sup>9</sup>/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">389 (46.3)</td><td valign="top" align="center" rowspan="1" colspan="1">254 (44.4)</td><td valign="top" align="center" rowspan="1" colspan="1">135 (50.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.123</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NEU%&#x02009;&#x0003e;&#x02009;75%, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">326 (38.8)</td><td valign="top" align="center" rowspan="1" colspan="1">196 (34.3)</td><td valign="top" align="center" rowspan="1" colspan="1">130 (48.5)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCT&#x02009;&#x0003c;&#x02009;45%, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">555 (66.1)</td><td valign="top" align="center" rowspan="1" colspan="1">352 (61.5)</td><td valign="top" align="center" rowspan="1" colspan="1">203 (75.8)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hb&#x02009;&#x0003c;&#x02009;120&#x02005;g/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (7.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PLT&#x02009;&#x0003e;&#x02009;300*10<sup>12</sup>/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">136 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">89 (15.6)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (17.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.532</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TBA&#x02009;&#x0003e;&#x02009;1.56&#x02005;umol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">395 (47.0)</td><td valign="top" align="center" rowspan="1" colspan="1">271 (47.4)</td><td valign="top" align="center" rowspan="1" colspan="1">124 (46.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.821</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TBil&#x02009;&#x0003e;&#x02009;17.1&#x02005;umol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">229 (27.3)</td><td valign="top" align="center" rowspan="1" colspan="1">145 (25.4)</td><td valign="top" align="center" rowspan="1" colspan="1">84 (31.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cr&#x02009;&#x0003e;&#x02009;110&#x02005;umol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.107</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">UA&#x02009;&#x0003e;&#x02009;360&#x02005;umol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">392 (46.7)</td><td valign="top" align="center" rowspan="1" colspan="1">279 (48.8)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (42.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.086</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCY&#x02009;&#x0003e;&#x02009;15&#x02005;umol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">280 (33.3)</td><td valign="top" align="center" rowspan="1" colspan="1">191 (33.4)</td><td valign="top" align="center" rowspan="1" colspan="1">89 (33.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glu&#x02009;&#x0003e;&#x02009;7.0&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">212 (25.2)</td><td valign="top" align="center" rowspan="1" colspan="1">140 (24.5)</td><td valign="top" align="center" rowspan="1" colspan="1">72 (26.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.510</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HbA1c&#x02009;&#x0003e;&#x02009;6.5%, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">176 (21.0)</td><td valign="top" align="center" rowspan="1" colspan="1">118 (20.6)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (21.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.806</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC&#x02009;&#x0003e;&#x02009;5.20&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">283 (33.7)</td><td valign="top" align="center" rowspan="1" colspan="1">193 (33.7)</td><td valign="top" align="center" rowspan="1" colspan="1">90 (33.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG&#x02009;&#x0003e;&#x02009;1.70&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">525 (62.5)</td><td valign="top" align="center" rowspan="1" colspan="1">362 (63.3)</td><td valign="top" align="center" rowspan="1" colspan="1">163 (60.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.541</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-C&#x02009;&#x0003e;&#x02009;3.40&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">339 (40.4)</td><td valign="top" align="center" rowspan="1" colspan="1">225 (39.3)</td><td valign="top" align="center" rowspan="1" colspan="1">114 (42.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.420</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-C&#x02009;&#x0003c;&#x02009;1.0&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">593 (70.6)</td><td valign="top" align="center" rowspan="1" colspan="1">414 (72.4)</td><td valign="top" align="center" rowspan="1" colspan="1">179 (66.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.115</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FFA&#x02009;&#x0003e;&#x02009;0.9&#x02005;mmol/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (9.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.187</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP&#x02009;&#x0003e;&#x02009;5.0&#x02005;mg/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">419 (49.9)</td><td valign="top" align="center" rowspan="1" colspan="1">249 (43.5)</td><td valign="top" align="center" rowspan="1" colspan="1">170 (63.4)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CLR&#x02009;&#x0003e;&#x02009;2.83, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">420 (50.0)</td><td valign="top" align="center" rowspan="1" colspan="1">246 (43.0)</td><td valign="top" align="center" rowspan="1" colspan="1">174 (64.9)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MLR&#x02009;&#x0003e;&#x02009;0.3 <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">420 (50.0)</td><td valign="top" align="center" rowspan="1" colspan="1">244 (42.7)</td><td valign="top" align="center" rowspan="1" colspan="1">176 (65.7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">D-dimer&#x02009;&#x0003e;&#x02009;0.5&#x02005;mg/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">110 (13.1)</td><td valign="top" align="center" rowspan="1" colspan="1">240 (42.0)</td><td valign="top" align="center" rowspan="1" colspan="1">168 (62.7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fg&#x02009;&#x0003e;&#x02009;4.0&#x02005;g/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">161 (19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">92 (16.1)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (25.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CK-MB&#x02009;&#x0003e;&#x02009;77 U/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">413 (49.2)</td><td valign="top" align="center" rowspan="1" colspan="1">259 (45.3)</td><td valign="top" align="center" rowspan="1" colspan="1">154 (57.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">cTnT&#x02009;&#x0003e;&#x02009;1.44&#x02005;ng/L, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">420 (50.0)</td><td valign="top" align="center" rowspan="1" colspan="1">255 (44.6)</td><td valign="top" align="center" rowspan="1" colspan="1">165 (61.6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BNP&#x02009;&#x0003e;&#x02009;100 pg/ml, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">601 (71.6)</td><td valign="top" align="center" rowspan="1" colspan="1">357 (62.4)</td><td valign="top" align="center" rowspan="1" colspan="1">244 (91.0)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Coronary angiography</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SYNTAX Score&#x02009;&#x0003e;&#x02009;14.5, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">418 (49.8)</td><td valign="top" align="center" rowspan="1" colspan="1">246 (43.0)</td><td valign="top" align="center" rowspan="1" colspan="1">172 (64.2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Three-vessel artery disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">255 (30.4)</td><td valign="top" align="center" rowspan="1" colspan="1">169 (29.6)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (32.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.505</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left main artery disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (3.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.087</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Complete coronary occlusion, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">452 (53.8)</td><td valign="top" align="center" rowspan="1" colspan="1">301 (52.6)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (56.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.350</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF (%)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (51, 58)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (50, 59)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (52, 58)</td><td valign="top" align="center" rowspan="1" colspan="1">0.943</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Symptoms and signs</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Jugular venous distension</td><td valign="top" align="center" rowspan="1" colspan="1">117 (13.93)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">117 (43.95)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary rales</td><td valign="top" align="center" rowspan="1" colspan="1">102 (12.14)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">102 (38.06)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leg edema</td><td valign="top" align="center" rowspan="1" colspan="1">58 (6.90)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">88 (21.64)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Killip class</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">792 (94.29)</td><td valign="top" align="center" rowspan="1" colspan="1">572 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">220 (82.09)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="center" rowspan="1" colspan="1">43 (5.12)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (16.04)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="center" rowspan="1" colspan="1">5 (0.60)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (1.87)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Medication during hospitalization</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aspirin</td><td valign="top" align="center" rowspan="1" colspan="1">840 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">572 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">268 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P2Y12 inhibitors</td><td valign="top" align="center" rowspan="1" colspan="1">840 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">572 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">268 (100.00)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Statins</td><td valign="top" align="center" rowspan="1" colspan="1">830 (98.81)</td><td valign="top" align="center" rowspan="1" colspan="1">563 (98.43)</td><td valign="top" align="center" rowspan="1" colspan="1">267 (99.63)</td><td valign="top" align="center" rowspan="1" colspan="1">0.135</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Beta-blockers</td><td valign="top" align="center" rowspan="1" colspan="1">645 (76.69)</td><td valign="top" align="center" rowspan="1" colspan="1">211 (78.73)</td><td valign="top" align="center" rowspan="1" colspan="1">434 (75.87)</td><td valign="top" align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACEI/ARB</td><td valign="top" align="center" rowspan="1" colspan="1">561 (66.79)</td><td valign="top" align="center" rowspan="1" colspan="1">379 (66.26)</td><td valign="top" align="center" rowspan="1" colspan="1">182 (67.91)</td><td valign="top" align="center" rowspan="1" colspan="1">0.636</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ARNI</td><td valign="top" align="center" rowspan="1" colspan="1">93 (11.07)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (11.19)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (11.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.938</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Loop diuretics</td><td valign="top" align="center" rowspan="1" colspan="1">30 (3.57)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (11.19)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MRA</td><td valign="top" align="center" rowspan="1" colspan="1">41(4.88)</td><td valign="top" align="center" rowspan="1" colspan="1">0(0.00)</td><td valign="top" align="center" rowspan="1" colspan="1">41(15.30)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; BNP, brain natriuretic peptide; CAD, coronary artery disease; CK-MB, creatine kinase isoenzyme; CLR, C-reactive protein to lymphocyte ratio; cTnT, cardiac troponin T; Cr, creatinine; CRP, C-reactive protein; DBP, diastolic blood pressure; FFA, free fatty acids; Fg, fibrinogen; Glu, glucose; Hb, hemoglobin; HbA1c, glycated hemoglobin; HCT, hematocrit; HCY, Homocysteine; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MLR, monocyte to lymphocyte ratio; MRA, mineralocorticoid receptor antagonist; NEU%, neutrophils percentage; NSTEMI, non-ST-segment elevation myocardial infarction; PLT, platelet; SBP, systolic blood pressure; STEMI, ST-segment elevation myocardial infarction; TBA, total bile acids; TBil, total bilirubin; TC, total cholesterol; TG, triglyceride; UA, uric acid; WBC, white blood cell.</p></fn></table-wrap-foot></table-wrap><p>In summary, the HFpEF cohort was characterized by older age, a higher burden of comorbidities, and more pronounced cardiovascular dysfunction compared to the Non-HF group.</p><p><xref rid="s12" ref-type="sec">Supplementary Table S2</xref> shows the baseline characteristics of the training set and testing set. <xref rid="s12" ref-type="sec">Supplementary Table S3</xref> shows the descriptive statistics of continuous variables.</p></sec><sec id="s3b"><title>Model construction</title><p>According to the ratio of 8:2, 840 patients were randomly divided into a training set and a testing set, with 672 in the training set and 168 in the testing set, and five different models were constructed in the training set. The VIF values are all below 5, indicating that multicollinearity is not a significant issue in our model.</p><p>Lasso regression screening (<xref rid="F2" ref-type="fig">Figures&#x000a0;2A,B</xref>) was performed on the full set of variables, identifying 12 key predictors: female sex, hypertension, STEMI, BMI &#x02265;24&#x02005;kg/m<sup>2</sup>, SYNTAX Score &#x0003e;14.5, admission HR &#x0003e;75&#x02005;bpm, NEU% &#x0003e;75%, HCT &#x0003c;45%, cTnT &#x0003e;1.44&#x02005;ng/L, MLR &#x0003e;0.3, CLR &#x0003e;2.83, and BNP &#x0003e;100&#x02005;pg/ml. Multivariate logistic regression modeling was carried out using the 12 variables from the screening. The final predictive model obtained consisted of 8 variables, which were female, BMI &#x02265;24&#x02005;kg/m<sup>2</sup>, SYNTAX Score &#x0003e;14.5, admission HR &#x0003e;75&#x02005;bpm, HCT &#x0003c;45%, MLR &#x0003e;0.3, CLR &#x0003e;2.83, and BNP &#x0003e;100&#x02005;pg/ml.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>(A)</bold> Lasso regression coefficients vs. <italic>&#x003bb;</italic> values; <bold>(B)</bold> cross-validated <italic>&#x003bb;</italic> and classification error plot relationships. Ranking of important variables based on Lasso-Logistic <bold>(C)</bold>, XGBoost <bold>(D)</bold>, RF <bold>(E)</bold>, KNN <bold>(F)</bold>, and SVM <bold>(G)</bold> models. BMI, body mass index; BNP, brain natriuretic peptide; CLR, C-reactive protein to lymphocyte ratio; cTnT, cardiac troponin T; Cr, creatinine; Fg, fibrinogen; Hb, hemoglobin; HbA1c, glycated hemoglobin; HCT, hematocrit; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; MLR, monocyte to lymphocyte ratio; NEU%, neutrophil percentage; SBP, systolic blood pressure; TC, total cholesterol; UA, uric acid; WBC, white blood cell.</p></caption><graphic xlink:href="fcvm-12-1571185-g002" position="float"/></fig><p>Following model training using RF, XGBoost, KNN, and SVM, the top 10 most important variables were identified and used for subsequent modeling. The ordering of important variables based on the Lasso-Logistic, XGBoost, RF, KNN, and SVM models are shown in <xref rid="F2" ref-type="fig">Figures&#x000a0;2C&#x02013;G</xref>, respectively.</p></sec><sec id="s3c"><title>Model performance</title><p>The classification performance of different models is compared in the testing set. (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>, <xref rid="F3" ref-type="fig">Figures&#x000a0;3A,B</xref>). Regarding discrimination, the AUC values of the five models range from 0.517&#x02013;0.854, with the highest being XGBoost and the lowest being SVM. The F1 score for combined precision and recall was the highest among the XGBoost models (0.586). A radar plot was made based on precision, accuracy, AUC, F1 score, and Brier score, which reflects the performance of each model (<xref rid="F3" ref-type="fig">Figure&#x000a0;3B</xref>). Although the XGBoost model predicts a lower accuracy than Lasso-Logistic (0.686 vs. 0.762), its AUC, accuracy, and F1 score are the highest, and its Brier score is comparable to Lasso-Logistic (0.143 vs. 0.143). <xref rid="s12" ref-type="sec">Supplementary Figure S1</xref> illustrates the class distribution of the training set before and after applying the SMOTE. The figure demonstrates that SMOTE effectively addresses class imbalance by generating synthetic samples for the minority class, ensuring a more balanced distribution for model training. We noticed improvements in the performance of most models, with the exception of SVM. In particular, the F1 score of the combined precision and recall, and the AUC of the XGBoost and KNN models also improved. Even after balancing the classes with SMOTE, XGBoost remained the best-performing model (<xref rid="s12" ref-type="sec">Supplementary Table S4</xref>). <xref rid="s12" ref-type="sec">Supplementary Table S5</xref> shows the NRI and IDI calculated for the XGBoost and four other models. The NRI calculated by the XGBoost model and Lasso-logistic was 0.149 (95% CI: 0.008&#x02013;0.290, <italic>P</italic>&#x02009;=&#x02009;0.039), and the IDI was 0.049 (95% CI: 0.008&#x02013;0.091, <italic>P</italic>&#x02009;=&#x02009;0.019). The NRI calculated by the XGBoost model and RF model was 0.222 (95% CI: 0.067&#x02013;0.377, <italic>P</italic>&#x02009;=&#x02009;0.005), and the IDI was 0.051 (95% CI: 0.015&#x02013;0.086, <italic>p</italic>&#x02009;=&#x02009;0.005). The NRI calculated by the XGBoost model and KNN model was 0.212 (95% CI: 0.028&#x02013;0.396, <italic>P</italic>&#x02009;=&#x02009;0.025), and the IDI was 0.067 (95% CI: 0.004&#x02013;0.130, <italic>p</italic>&#x02009;=&#x02009;0.038). The NRI calculated with the XGBoost model and the SVM model was 0.428 (95%CI: 0.277&#x02013;0.579, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and the IDI was 0.227 (95% CI: 0.175&#x02013;0.279, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). These results indicate that the XGBoost model demonstrates stronger predictive ability compared to the other models.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Classification performance of five models on the testing set.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Model</th><th valign="top" align="center" rowspan="1" colspan="1">Precision</th><th valign="top" align="center" rowspan="1" colspan="1">Accuracy</th><th valign="top" align="center" rowspan="1" colspan="1">AUC</th><th valign="top" align="center" rowspan="1" colspan="1">F1 score</th><th valign="top" align="center" rowspan="1" colspan="1">Brier score</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Lasso-Logistic</td><td valign="top" align="center" rowspan="1" colspan="1">0.762</td><td valign="top" align="center" rowspan="1" colspan="1">0.786</td><td valign="top" align="center" rowspan="1" colspan="1">0.851</td><td valign="top" align="center" rowspan="1" colspan="1">0.470</td><td valign="top" align="center" rowspan="1" colspan="1">0.143</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">XGBoost</td><td valign="top" align="center" rowspan="1" colspan="1">0.686</td><td valign="top" align="center" rowspan="1" colspan="1">0.798</td><td valign="top" align="center" rowspan="1" colspan="1">0.854</td><td valign="top" align="center" rowspan="1" colspan="1">0.586</td><td valign="top" align="center" rowspan="1" colspan="1">0.143</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RF</td><td valign="top" align="center" rowspan="1" colspan="1">0.667</td><td valign="top" align="center" rowspan="1" colspan="1">0.756</td><td valign="top" align="center" rowspan="1" colspan="1">0.846</td><td valign="top" align="center" rowspan="1" colspan="1">0.369</td><td valign="top" align="center" rowspan="1" colspan="1">0.155</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KNN</td><td valign="top" align="center" rowspan="1" colspan="1">0.516</td><td valign="top" align="center" rowspan="1" colspan="1">0.726</td><td valign="top" align="center" rowspan="1" colspan="1">0.726</td><td valign="top" align="center" rowspan="1" colspan="1">0.410</td><td valign="top" align="center" rowspan="1" colspan="1">0.177</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SVM</td><td valign="top" align="center" rowspan="1" colspan="1">0.280</td><td valign="top" align="center" rowspan="1" colspan="1">0.280</td><td valign="top" align="center" rowspan="1" colspan="1">0.517</td><td valign="top" align="center" rowspan="1" colspan="1">0.438</td><td valign="top" align="center" rowspan="1" colspan="1">0.204</td></tr></tbody></table></table-wrap><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>(A)</bold> ROC curve of five algorithms; <bold>(B)</bold> Radar plot of precision, accuracy, AUC, F1 score, and Brier score of the five models; Calibration curves of the XGBoost model in the training set <bold>(C)</bold> and testing set <bold>(D)</bold> DCA of the XGBoost model in the training set <bold>(E)</bold> and testing set <bold>(F)</bold>.</p></caption><graphic xlink:href="fcvm-12-1571185-g003" position="float"/></fig><p>Calibration curves show that the predicted probabilities of the XGBoost model are in good agreement with the actual probabilities (<xref rid="F3" ref-type="fig">Figures&#x000a0;3C,D</xref>). The DCA plot (<xref rid="F3" ref-type="fig">Figures&#x000a0;3E,F</xref>) demonstrates that the XGBoost model provides positive net benefits across a range of threshold probabilities in both the training and testing sets. This suggests that the model has strong clinical utility in aiding clinicians with accurate risk assessment and decision-making for PMI patients. In conclusion, the XGBoost model was selected as the final model based on its superior performance.</p></sec><sec id="s3d"><title>Importance ranking</title><p>The XGBoost model's variables' importance ranking showed that BNP &#x0003e;100 pg/ml is the most important characteristic influencing the occurrence of in-hospital HFpEF in patients with PMI. In addition, SYNTAX Score &#x0003e;14.5, Age, MLR &#x0003e;0.3, HCT &#x0003c;45%, HR &#x0003e;75&#x02005;bpm, BMI &#x02265;24&#x02005;kg/m<sup>2</sup>, CLR &#x0003e;2.83, Hypertension, and Fg &#x02265;4&#x02005;g/L were also important variables in predicting HFpEF (<xref rid="F2" ref-type="fig">Figure&#x000a0;2D</xref>). <xref rid="F4" ref-type="fig">Figure&#x000a0;4A</xref> and <xref rid="s12" ref-type="sec">Supplementary Table S6</xref> shows that the above variables were risk factors for in-hospital HFpEF in patients with PMI.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>(A)</bold> Forest plot with 10 important variables based on the XGBoost model. <bold>(B)</bold> Visual online prediction system based on the XGBoost model. The input interface is on the left, and the output interface is on the right. The upper part of the right represents the prediction probability, and the lower part of the right shows an individualized SHAP diagram. The red feature makes the model recognize the sample as class 1, while the blue feature makes the model identify the sample as class 0. BMI, body mass index; BNP, brain natriuretic peptide; CLR, C-reactive protein to lymphocyte ratio; Fg, fibrinogen; HCT, hematocrit; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, heart rate; MLR, monocyte to lymphocyte ratio.</p></caption><graphic xlink:href="fcvm-12-1571185-g004" position="float"/></fig></sec><sec id="s3e"><title>Visual prediction system</title><p>The visual prediction system includes an input interface (left) for entering patient variables (e.g., age, hypertension status) and an output interface (right) displaying predicted probabilities (top) and individualized SHAP charts explaining model decisions (bottom). In <xref rid="F4" ref-type="fig">Figure&#x000a0;4B</xref>, the system predicts a 65.5% probability of HFpEF for a PMI patient based on clinical inputs. The system is publicly accessible at <ext-link xlink:href="https://hfpefpmi.shinyapps.io/apppredict/" ext-link-type="uri">https://hfpefpmi.shinyapps.io/apppredict/</ext-link>.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this study, we explored five ML methods to build a prediction model for HFpEF in PMI patients based on clinically accessible data. The model developed by XGBoost has superior prediction performance and can better predict whether HFpEF occurs in the hospital in patients with PMI. Based on the ranking of variable importance, the final model includes ten predictive variables: BNP&#x02009;&#x0003e;&#x02009;100 pg/ml, SYNTAX Score &#x0003e;14.5, Age, MLR &#x0003e;0.3, HCT &#x0003c;45%, HR &#x0003e;75&#x02005;bpm, BMI &#x02265;24&#x02005;kg/m<sup>2</sup>, CLR &#x0003e;2.83, Hypertension, and Fg &#x0003e;4&#x02005;g/L. In addition, establishing a visual online prediction system will facilitate a more convenient clinical application, which can calculate the prediction probability of in-hospital HFpEF in PMI patients. As a model explanation, SHAP can show how each variable affects the model prediction and the degree of influence.</p><p>To our knowledge, this is the first study to develop an in-hospital HFpEF prediction model for PMI patients using ML algorithms. Previous studies, such as Liang et al. (<xref rid="B26" ref-type="bibr">26</xref>) and Xu et al. (<xref rid="B27" ref-type="bibr">27</xref>), primarily relied on logistic regression models to identify risk factors for HF in AMI patients. While logistic regression offers advantages in model interpretability and statistical rigor, it struggles to capture complex nonlinear interactions, potentially underestimating the influence of key variables. Given the highly heterogeneous pathophysiology of HFpEF, this study employs the XGBoost algorithm, which excels in identifying nonlinear relationships and intricate variable interactions, making it particularly suitable for HFpEF prediction. Our model incorporates multidimensional predictive factors, including SYNTAX score to assess coronary complexity, inflammatory markers (CLR, MLR), metabolic risk factors (BMI, hypertension), and dynamic biomarker thresholds (e.g., BNP &#x0003e;100&#x02005;pg/ml), enabling more refined risk stratification. Unlike previous methods that primarily relied on static OR values, we implemented SHAP-based visualization analysis, which enhances model transparency and mitigates the &#x0201c;black-box&#x0201d; issue commonly associated with ML applications in clinical practice.</p><p>In recent years, Li et al. (<xref rid="B28" ref-type="bibr">28</xref>) demonstrated the potential of machine learning in predicting HF after AMI. Li et al. compared seven ML algorithms and identified XGBoost as the best-performing model (AUC&#x02009;=&#x02009;0.966). However, their study primarily focused on general HF prediction rather than specifically addressing HFpEF as a distinct subtype. In contrast, our study is dedicated to HFpEF risk prediction, filling a critical gap in early risk stratification for PMI patients. Additionally, we developed an interpretable and real-time visualization tool, which can assist clinicians in rapidly assessing HFpEF risk in clinical practice. However, unlike Li et al. (<xref rid="B28" ref-type="bibr">28</xref>) which conducted external validation using an independent patient cohort, our study has not yet undergone multi-center external validation. Future research should focus on evaluating the model's stability and generalizability across different hospitals and populations, ensuring its clinical applicability and scalability.</p><p>The epidemiology of HF after AMI has undergone significant changes over the past decades, with an increased proportion of HFpEF and a mortality rate comparable to that of patients with Heart Failure with Reduced Ejection Fraction (HFrEF) (<xref rid="B29" ref-type="bibr">29</xref>). HFpEF is a heterogeneous systemic disease in which risk factors such as aging, obesity, hypertension, and systemic metabolic disorders may impair cardiac, pulmonary, vascular, and peripheral reserve capacity, abnormalities not apparent in the resting state (<xref rid="B30" ref-type="bibr">30</xref>). Damage and necrosis of cardiomyocytes after AMI can lead to impaired systolic reserve, and changes in cardiomyocyte and interstitial structure, such as cardiomyocyte hypertrophy and increased collagen fiber content, can lead to impaired diastolic reserve (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>).</p><p>Doshi et al. (<xref rid="B33" ref-type="bibr">33</xref>) studied the characteristics of HFpEF occurring during hospitalization in STEMI patients undergoing PCI and showed that older age, a higher proportion of females, and more comorbidities were risk factors for HFpEF. The SYNTAX Score, which reflects the extent of coronary artery disease, is also an essential factor in HFpEF. Complex coronary artery disease indicates the presence of a more significant atherosclerotic burden. The prevalence of HFpEF is strongly associated with metabolic syndrome epidemics, and obesity may be a significant driver of HFpEF in young people (<xref rid="B34" ref-type="bibr">34</xref>). The prevalence of subclinical left ventricular dysfunction has been confirmed to occur in Asians at lower BMI thresholds (<xref rid="B35" ref-type="bibr">35</xref>). In this study, HFpEF was predicted in young AMI patients with a BMI &#x02265;24&#x02005;kg/m<sup>2</sup>. In addition to the traditional belief that hypertension leads to increased left ventricular afterload, causing left ventricular hypertrophy and subsequent left ventricular diastolic dysfunction, the pro-inflammatory state resulting from systemic hypertension also promotes the development of HFpEF (<xref rid="B36" ref-type="bibr">36</xref>). HFpEF is also manifested by elevated circulating inflammatory biomarkers, and the results of the present study suggest that inflammatory markers such as CLR, MLR, and Fg. On the other hand, the increase of Fg indicates increased clotting ability and impaired blood flow. Additionally, our study demonstrates a significant gender disparity, with a markedly higher prevalence of HFpEF among PMI patients compared to males (15.7% vs. 5.9%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). This finding is consistent with existing literature on sex-specific comorbidity burden and adverse outcomes following AMI in young women (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). It highlights the need for early identification and gender-specific management strategies to improve outcomes in this vulnerable population.</p><p>Combined with the predictive factors discussed in this study, for high-risk patients, first-line treatment includes early use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors for patients without contraindications and diuretics for patients with evident hyperemia to maintain average blood volume (<xref rid="B2" ref-type="bibr">2</xref>). Revascularization treatment should be carried out for patients with complex vascular lesions as soon as possible, and related risk factors should be controlled. Patients should insist on taking medicine, limit sodium, calorie, and fluid intake, control blood pressure, and monitor BNP and inflammatory markers.</p><p>In this study, we investigated for the first time the risk factors and characteristics of in-hospital HFpEF in young patients with AMI and developed a prediction model. With the prevalence of metabolic syndrome in young people, the incidence of HFpEF is increasing, and the prognosis is poor; more attention should be given to the young population. In addition, the XGBoost algorithm can enhance the performance of the prediction model, and there has not been a previous attempt to apply the ML algorithm to predict the risk of in-hospital HFpEF in patients with PMI. This study has several limitations. First, the single-center design may limit generalizability despite internal cross-validation. Second, although the sample size was sufficient for preliminary model development, a larger cohort is necessary to validate feature stability and improve model robustness. The limited sample size might affect model robustness. Third, future studies should incorporate additional clinical dimensions including lifestyle factors (e.g., diet, physical activity), medication histories, socioeconomic parameters, and genetic profiles to improve predictive performance. Finally, external validation across diverse populations remains essential before clinical implementation.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>In this study, a new model was developed to predict the risk of in-hospital HFpEF in PMI patients. In a comprehensive comparison, the XGBoost model had the best predictive ability. The XGBoost-based visual prediction system shows clinical decision-support potential for PMI management, pending rigorous external validation in diverse clinical settings. Following successful validation, it could provide early and precise intervention guidance for PMI patients to reduce HFpEF incidence and improve long-term prognosis.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors especially thank all the selected patients for their participation.</p></ack><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s12" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by The Ethics Committee of Tianjin Chest Hospital (No. 2017KY-007-01). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>JW: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. CL: Conceptualization, Methodology, Supervision, Writing &#x02013; review &#x00026; editing. ZC: Methodology, Writing &#x02013; review &#x00026; editing. YLia: Data curation, Investigation, Writing &#x02013; original draft. YW: Data curation, Investigation, Writing &#x02013; original draft. YZ: Data curation, Visualization, Writing &#x02013; original draft. YLiu: Methodology, Supervision, Writing &#x02013; review &#x00026; editing. JG: Conceptualization, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s13"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fcvm.2025.1571185/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fcvm.2025.1571185/full#supplementary-material</ext-link></p><supplementary-material id="SD1" position="float" content-type="local-data"><media xlink:href="Table1.docx" id="d100e1670" position="anchor"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jen&#x0010d;a</surname><given-names>D</given-names></name><name><surname>Melenovsk&#x000fd;</surname><given-names>V</given-names></name><name><surname>Stehlik</surname><given-names>J</given-names></name><name><surname>Stan&#x0011b;k</surname><given-names>V</given-names></name><name><surname>Kettner</surname><given-names>J</given-names></name><name><surname>Kautzner</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Heart failure after myocardial infarction: incidence and predictors</article-title>. <source>ESC Heart Failure</source>. (<year>2021</year>) <volume>8</volume>:<fpage>222</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.13144</pub-id><pub-id pub-id-type="pmid">33319509</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redfield</surname><given-names>MM</given-names></name><name><surname>Borlaug</surname><given-names>BA</given-names></name></person-group>. <article-title>Heart failure with preserved ejection fraction: a review</article-title>. <source>JAMA</source>. (<year>2023</year>) <volume>329</volume>:<fpage>827</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2023.2020</pub-id><pub-id pub-id-type="pmid">36917048</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>JW</given-names></name><name><surname>Vaduganathan</surname><given-names>M</given-names></name><name><surname>Claggett</surname><given-names>BL</given-names></name><name><surname>John</surname><given-names>JE</given-names></name><name><surname>Desai</surname><given-names>AS</given-names></name><name><surname>Lewis</surname><given-names>EF</given-names></name><etal/></person-group>
<article-title>Myocardial infarction in heart failure with preserved ejection fraction</article-title>. <source>JACC Heart Fail</source>. (<year>2020</year>) <volume>8</volume>:<fpage>618</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jchf.2020.02.007</pub-id><pub-id pub-id-type="pmid">32387067</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elgendy</surname><given-names>IY</given-names></name><name><surname>Mahtta</surname><given-names>D</given-names></name><name><surname>Pepine</surname><given-names>CJ</given-names></name></person-group>. <article-title>Medical therapy for heart failure caused by ischemic heart disease</article-title>. <source>Circ Res</source>. (<year>2019</year>) <volume>124</volume>:<fpage>1520</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313568</pub-id><pub-id pub-id-type="pmid">31120824</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popat</surname><given-names>A</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>SK</given-names></name><name><surname>Baddevolu</surname><given-names>S</given-names></name><name><surname>Adusumilli</surname><given-names>S</given-names></name><name><surname>Rao Dasari</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Artificial intelligence in the early prediction of cardiogenic shock in acute heart failure or myocardial infarction patients: a systematic review and meta-analysis</article-title>. <source>Cureus</source>. (<year>2023</year>) <volume>15</volume>:<fpage>e50395</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.50395</pub-id><pub-id pub-id-type="pmid">38213372</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kresoja</surname><given-names>K-P</given-names></name><name><surname>Unterhuber</surname><given-names>M</given-names></name><name><surname>Wachter</surname><given-names>R</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name><name><surname>Lurz</surname><given-names>P</given-names></name></person-group>. <article-title>A cardiologist&#x02019;s guide to machine learning in cardiovascular disease prognosis prediction</article-title>. <source>Basic Res Cardiol</source>. (<year>2023</year>) <volume>118</volume>:<fpage>10</fpage>. <pub-id pub-id-type="doi">10.1007/s00395-023-00982-7</pub-id><pub-id pub-id-type="pmid">36939941</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Guestrin</surname><given-names>C</given-names></name></person-group>. <article-title>XGBoost: A Scalable Tree Boosting System</article-title>. Edited by. ACM. 785&#x02013;794 (2016).</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Predicting the prognosis of patients in the coronary care unit: a novel multi-category machine learning model using XGBoost</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<fpage>764629</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.764629</pub-id><pub-id pub-id-type="pmid">35647052</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scrutinio</surname><given-names>D</given-names></name><name><surname>Amitrano</surname><given-names>F</given-names></name><name><surname>Guida</surname><given-names>P</given-names></name><name><surname>Coccia</surname><given-names>A</given-names></name><name><surname>Pagano</surname><given-names>G</given-names></name><name><surname>D'addio</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Prediction of mortality in heart failure by machine learning. Comparison with statistical modeling</article-title>. <source>Eur J Intern Med</source>. (<year>2025</year>) <volume>133</volume>:<fpage>106</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejim.2025.01.020</pub-id><pub-id pub-id-type="pmid">39880777</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Younis</surname><given-names>SM</given-names></name><name><surname>Hadjileontiadis</surname><given-names>LJ</given-names></name><name><surname>Khandoker</surname><given-names>AH</given-names></name><name><surname>Stefanini</surname><given-names>C</given-names></name><name><surname>Soulaidopoulos</surname><given-names>S</given-names></name><name><surname>Arsenos</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Prediction of heart failure patients with distinct left ventricular ejection fraction levels using circadian ECG features and machine learning</article-title>. <source>PLoS One</source>. (<year>2024</year>) <volume>19</volume>:<fpage>e302639</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0302639</pub-id><pub-id pub-id-type="pmid">38739639</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>F-J</given-names></name><name><surname>Chen</surname><given-names>X-H</given-names></name><name><surname>Quan</surname><given-names>X-Q</given-names></name><name><surname>Wang</surname><given-names>L-L</given-names></name><name><surname>Wei</surname><given-names>X-Y</given-names></name><name><surname>Zhu</surname><given-names>J-L</given-names></name></person-group>. <article-title>Development and validation of an interpretable machine learning model&#x02014;predicting mild cognitive impairment in a high-risk stroke population</article-title>. <source>Front Aging Neurosci</source>. (<year>2023</year>) <volume>15</volume>:<fpage>1180351</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2023.1180351</pub-id><pub-id pub-id-type="pmid">37396650</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Sheng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Prediction of hematoma expansion in spontaneous intracerebral hemorrhage using support vector machine</article-title>. <source>EBioMedicine</source>. (<year>2019</year>) <volume>43</volume>:<fpage>454</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.04.040</pub-id><pub-id pub-id-type="pmid">31060901</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golas</surname><given-names>SB</given-names></name><name><surname>Shibahara</surname><given-names>T</given-names></name><name><surname>Agboola</surname><given-names>S</given-names></name><name><surname>Otaki</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>J</given-names></name><name><surname>Nakae</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A machine learning model to predict the risk of 30-day readmissions in patients with heart failure: a retrospective analysis of electronic medical records data</article-title>. <source>BMC Med Inform Decis Mak</source>. (<year>2018</year>) <volume>18</volume>:<fpage>44</fpage>. <pub-id pub-id-type="doi">10.1186/s12911-018-0620-z</pub-id><pub-id pub-id-type="pmid">29929496</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>DT</given-names></name><name><surname>Azizi</surname><given-names>P</given-names></name><name><surname>Bouadjenek</surname><given-names>MR</given-names></name><name><surname>Koh</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Evaluation of machine learning algorithms for predicting readmission after acute myocardial infarction using routinely collected clinical data</article-title>. <source>Can J Cardiol</source>. (<year>2020</year>) <volume>36</volume>:<fpage>878</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2019.10.023</pub-id><pub-id pub-id-type="pmid">32204950</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>Predicting mortality in intensive care unit patients with heart failure using an interpretable machine learning model: retrospective cohort study</article-title>. <source>J Med Internet Res</source>. (<year>2022</year>) <volume>24</volume>:<fpage>e38082</fpage>. <pub-id pub-id-type="doi">10.2196/38082</pub-id><pub-id pub-id-type="pmid">35943767</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Comparison of prediction models for acute kidney injury among patients with hepatobiliary malignancies based on XGBoost and LASSO-logistic algorithms</article-title>. <source>Int J Gen Med</source>. (<year>2021</year>) <volume>14</volume>:<fpage>1325</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.2147/IJGM.S302795</pub-id><pub-id pub-id-type="pmid">33889012</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Y-J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Postoperative delirium prediction after cardiac surgery using machine learning models</article-title>. <source>Comput Biol Med</source>. (<year>2024</year>) <volume>169</volume>:<fpage>107818</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiomed.2023.107818</pub-id><pub-id pub-id-type="pmid">38134752</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><etal/></person-group>
<article-title>Fourth universal definition of myocardial infarction (2018)</article-title>. <source>Eur Heart J</source>. (<year>2019</year>) <volume>40</volume>:<fpage>237</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehy462</pub-id><pub-id pub-id-type="pmid">30165617</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Simoons</surname><given-names>ML</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><etal/></person-group>
<article-title>Third universal definition of myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. (<year>2012</year>) <volume>60</volume>:<fpage>1581</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2012.08.001</pub-id><pub-id pub-id-type="pmid">22958960</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sianos</surname><given-names>G</given-names></name><name><surname>Morel</surname><given-names>MA</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Dawkins</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease</article-title>. <source>EuroIntervention</source>. (<year>2005</year>) <volume>1</volume>:<fpage>219</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.4244/EIJV1I2A36</pub-id><pub-id pub-id-type="pmid">19758907</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>TA</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Adamo</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>RS</given-names></name><name><surname>Baumbach</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure</article-title>. <source>Eur Heart J</source>. (<year>2021</year>) <volume>42</volume>:<fpage>3599</fpage>&#x02013;<lpage>726</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehab368</pub-id><pub-id pub-id-type="pmid">34447992</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Voors</surname><given-names>AA</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Cleland</surname><given-names>JGF</given-names></name><name><surname>Coats</surname><given-names>AJS</given-names></name><etal/></person-group>
<article-title>2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC</article-title>. <source>Eur Heart J</source>. (<year>2016</year>) <volume>37</volume>:<fpage>2129</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehw128</pub-id><pub-id pub-id-type="pmid">27206819</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>RD</given-names></name><name><surname>Snell</surname><given-names>KI</given-names></name><name><surname>Ensor</surname><given-names>J</given-names></name><name><surname>Burke</surname><given-names>DL</given-names></name><name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></name><name><surname>Moons</surname><given-names>KG</given-names></name><etal/></person-group>
<article-title>Minimum sample size for developing a multivariable prediction model: PART II&#x02014;binary and time-to-event outcomes</article-title>. <source>Stat Med</source>. (<year>2019</year>) <volume>38</volume>:<fpage>1276</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1002/sim.7992</pub-id><pub-id pub-id-type="pmid">30357870</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>BF</given-names></name></person-group>. <article-title>Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults&#x02013;study on optimal cut-off points of body mass index and waist circumference in Chinese adults</article-title>. <source>Biomed Environ Sci</source>. (<year>2002</year>) <volume>15</volume>:<fpage>83</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">12046553</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>NV</given-names></name><name><surname>Bowyer</surname><given-names>KW</given-names></name><name><surname>Hall</surname><given-names>LO</given-names></name><name><surname>Kegelmeyer</surname><given-names>WP</given-names></name></person-group>. <article-title>SMOTE: synthetic minority over-sampling technique</article-title>. <source>J Artif Intell Res</source>. (<year>2002</year>) <volume>16</volume>:<fpage>321</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1613/jair.953</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>. <article-title>Predictors of in-hospital heart failure in patients with acute anterior wall ST-segment elevation myocardial infarction</article-title>. <source>Int J Cardiol</source>. (<year>2023</year>) <volume>375</volume>:<fpage>104</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2023.01.002</pub-id><pub-id pub-id-type="pmid">36638919</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name></person-group>. <article-title>Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction</article-title>. <source>Medicine (Baltimore)</source>. (<year>2018</year>) <volume>97</volume>:<fpage>e11093</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000011093</pub-id><pub-id pub-id-type="pmid">29901624</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group>. <article-title>Development and comparison of machine learning-based models for predicting heart failure after acute myocardial infarction</article-title>. <source>BMC Med Inform Decis Mak</source>. (<year>2023</year>) <volume>23</volume>:<fpage>165</fpage>. <pub-id pub-id-type="doi">10.1186/s12911-023-02240-1</pub-id><pub-id pub-id-type="pmid">37620904</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>Y</given-names></name><name><surname>Weston</surname><given-names>SA</given-names></name><name><surname>Berardi</surname><given-names>C</given-names></name><name><surname>McNallan</surname><given-names>SM</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name><etal/></person-group>
<article-title>Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study</article-title>. <source>Am J Epidemiol</source>. (<year>2013</year>) <volume>178</volume>:<fpage>1272</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwt109</pub-id><pub-id pub-id-type="pmid">23997209</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Buono</surname><given-names>MG</given-names></name><name><surname>Iannaccone</surname><given-names>G</given-names></name><name><surname>Scacciavillani</surname><given-names>R</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Camilli</surname><given-names>M</given-names></name><name><surname>Niccoli</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence</article-title>. <source>Prog Cardiovasc Dis</source>. (<year>2020</year>) <volume>63</volume>:<fpage>570</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.pcad.2020.04.011</pub-id><pub-id pub-id-type="pmid">32387101</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Buono</surname><given-names>MG</given-names></name><name><surname>Garmendia</surname><given-names>CM</given-names></name><name><surname>Seropian</surname><given-names>IM</given-names></name><name><surname>Gonzalez</surname><given-names>G</given-names></name><name><surname>Berrocal</surname><given-names>DH</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Heart failure after ST-elevation myocardial infarction: beyond left ventricular adverse remodeling</article-title>. <source>Curr Probl Cardiol</source>. (<year>2023</year>) <volume>48</volume>:<fpage>101215</fpage>. <pub-id pub-id-type="doi">10.1016/j.cpcardiol.2022.101215</pub-id><pub-id pub-id-type="pmid">35460680</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>L</given-names></name><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Bacal</surname><given-names>F</given-names></name><name><surname>Makdisse</surname><given-names>MR</given-names></name><name><surname>Correa</surname><given-names>AG</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction</article-title>. <source>Arq Bras Cardiol</source>. (<year>2015</year>) <volume>105</volume>:<fpage>145</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.5935/abc.20150055</pub-id><pub-id pub-id-type="pmid">26039659</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Meraj</surname><given-names>P</given-names></name></person-group>. <article-title>Characteristics and in-hospital outcomes of hospitalisations with heart failure with reduced or preserved ejection fraction undergoing percutaneous coronary intervention</article-title>. <source>Ir J Med Sci</source>. (<year>2019</year>) <volume>188</volume>:<fpage>791</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s11845-018-1910-2</pub-id><pub-id pub-id-type="pmid">30328085</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tromp</surname><given-names>J</given-names></name><name><surname>MacDonald</surname><given-names>MR</given-names></name><name><surname>Tay</surname><given-names>WT</given-names></name><name><surname>Teng</surname><given-names>T-HK</given-names></name><name><surname>Hung</surname><given-names>C-L</given-names></name><name><surname>Narasimhan</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Heart failure with preserved ejection fraction in the young</article-title>. <source>Circulation</source>. (<year>2018</year>) <volume>138</volume>:<fpage>2763</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034720</pub-id><pub-id pub-id-type="pmid">30565987</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>YH</given-names></name><name><surname>Liu</surname><given-names>ME</given-names></name><name><surname>Su</surname><given-names>CH</given-names></name><name><surname>Yun</surname><given-names>C-H</given-names></name><name><surname>Liu</surname><given-names>C-Y</given-names></name><name><surname>Hou</surname><given-names>CJ-Y</given-names></name><etal/></person-group>
<article-title>Obesity-related changes in cardiac structure and function among Asian men and women</article-title>. <source>J Am Coll Cardiol</source>. (<year>2017</year>) <volume>69</volume>:<fpage>2876</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.04.016</pub-id><pub-id pub-id-type="pmid">28595707</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemenza</surname><given-names>F</given-names></name><name><surname>Citarrella</surname><given-names>R</given-names></name><name><surname>Patti</surname><given-names>A</given-names></name><name><surname>Rizzo</surname><given-names>M</given-names></name></person-group>. <article-title>Obesity and HFpEF</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>:<fpage>3858</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11133858</pub-id><pub-id pub-id-type="pmid">35807143</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawano</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Caraballo</surname><given-names>C</given-names></name><name><surname>Mahajan</surname><given-names>S</given-names></name><name><surname>Dreyer</surname><given-names>R</given-names></name><name><surname>Lichtman</surname><given-names>JH</given-names></name><etal/></person-group>
<article-title>Sex difference in outcomes of acute myocardial infarction in young patients</article-title>. <source>J Am Coll Cardiol</source>. (<year>2023</year>) <volume>81</volume>:<fpage>1797</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2023.03.383</pub-id><pub-id pub-id-type="pmid">37137590</pub-id>
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izadnegahdar</surname><given-names>M</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>CR</given-names></name><name><surname>Kopec</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years</article-title>. <source>J Women&#x02019;s Health</source>. (<year>2014</year>) <volume>23</volume>:<fpage>10</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/jwh.2013.4507</pub-id></mixed-citation></ref></ref-list></back></article>